Can-Fite BioPharma Ltd.

CANF • Biotechnology

$2.23

▼ -0.12 (-5.11%)

Current price

EarningsLatest report: Dec 31, 2025

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$720.89M

Growth

-23.2%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.01Healthy liquidity · 3.46Negative growth trendWeak profitability

Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Mar 26, 2026, 12:00 AM UTCLast profile update: Sep 2, 2026, 12:17 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.23

Change-5.11%

Shares Out323.27M

Market Cap$720.89M

Enterprise Value$712.35M

52W Range2.56 - 13.40

Beta0.02

P/E-73.35

P/S1,779.97

P/B128.91

P/FCF-80.54

EV/Sales1,758.89

Price$2.23

Change-5.11%

Shares Out323.27M

Market Cap$720.89M

Enterprise Value$712.35M

52W Range2.56 - 13.40

Beta0.02

P/E-73.35

P/S1,779.97

P/B128.91

P/FCF-80.54

EV/Sales1,758.89

EV/EBITDA-71.77

EV/FCF-79.58

Earnings Yield-1.36%

FCF Yield-1.24%

Dividend Yield0.00%

Gross Margin94.07%

Oper. Margin-24.57%

Profit Margin-24.27%

Debt/Eq0.01

Current Ratio3.46

Quick Ratio3.46

Revenue 5Y-23.15%

Target$8.00

Target Upside258.74%

Target Median$8.00

Target Range8.00 - 8.00

Volume15.32K

Avg Volume1.32M

EPS Surprise21.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

75/100

Why this score▼

Manageable debt level · 0.01Healthy liquidity · 3.46Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

CANF

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Price Target

2026-09-02

Low

$8.00

Mean

$8.00

Median

$8.00

High

$8.00

Company Overview

IPO: 11/6/2012

Industry: Biotechnology

P/B i: 128.91

Debt / Equity i: 0.01

Operating Margin: -2456.80%

Net Margin: -2426.67%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.01

Current Ratio: 3.46

Quick Ratio: 3.46

Status: Good

Insider Transactions

Recent executive and insider activity

Fishman Pnina

Transaction: 06/04/2026

BUY

Change

+24,000

Price

$2.04

Filing

06/08/2026

Type

BUY

Farbstein Motti

Transaction: 06/04/2026

BUY

Change

+24,000

Price

$2.04

Filing

06/08/2026

Type

BUY

Tamir Ilan

Transaction: 04/25/2026

OTHER

Change

+16,000

Price

$2.25

Filing

04/23/2026

Type

OTHER

Insider	Type	Change	Price	Transaction	Filing
Fishman Pnina	BUY	+24,000	$2.04	06/04/2026	06/08/2026
Farbstein Motti	BUY	+24,000	$2.04	06/04/2026	06/08/2026
Tamir Ilan	OTHER	+16,000	$2.25	04/25/2026	04/23/2026
Regev Guy	OTHER	+16,000	$2.18	04/25/2026	04/06/2026
Regev Guy	OTHER	0	Not reported	03/18/2026	04/06/2026
Regev Guy	OTHER	+2,166	$26.56	08/07/2024	04/06/2026
Regev Guy	OTHER	+2,166	$25.21	08/01/2023	04/06/2026
Regev Guy	OTHER	+200	$241.47	06/15/2020	04/06/2026
Regev Guy	OTHER	+16	$2826.14	02/08/2017	04/06/2026
Bornstein Yoseph	OTHER	+16,000	$2.18	04/25/2026	03/18/2026
Bornstein Yoseph	OTHER	+2,166	$26.56	08/07/2024	03/18/2026
Bornstein Yoseph	OTHER	+2,166	$25.21	08/01/2023	03/18/2026
Bornstein Yoseph	OTHER	+200	$241.47	06/22/2021	03/18/2026

About the Company

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Source - link

Peers

BDRX CLDI CMND CNSP GRI JAGX KZIA OGEN SILO SNGX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.

Benzinga

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.

GlobeNewsWire

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

GlobeNewsWire

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer.

GlobeNewsWire

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-03-26	-26.9973	-5.97	21.0273
2025-04-14	-0.24	-0.21437	0.02563
2024-12-26	-0.27	-0.43	-0.16
2024-09-26	-0.36	-0.4	-0.04
2024-06-27	-0.4	-0.65	-0.25
2024-03-28	-5.4	-6.2	-0.8
2023-11-30	-8.6	-8.6	0
2023-08-31	-10.8	-8	2.8
2023-06-01	-1.52	-13	-11.48
2023-03-30	-11.4	-22.2	-10.8
2022-11-25	-20	-18	2
2022-08-25	-18	-16	2